Personalized medicine in cancer: liquid biopsy-based biomarkers
Year: 2021
Type: dissertation
Study design: Observational Study
Abstract: Liquid biopsy is a non-invasive approach that provides tumour molecular profiling and may assist in the management of cancer patients. Therefore, here we investigated the utility of liquid biopsy-based biomarkers as prognostic tools in metastatic pancreatic ductal adenocarcinoma (PDAC) and metastatic colorectal cancer (CRC) patients. Specifically, circulating cell-free DNA (cfDNA) level and fragmentation were determined in plasma, and BEAMing technique was used for quantitative determination of RAS mutation allele fraction (MAF) in cfDNA. Additionally, a TaqMan real-time PCR assay was used to quantify basal circulating levels of 754 microRNAs (miRNAs) in plasma of metastatic CRC patients treated with anti-angiogenic therapy. For pancreatic cancer studies, plasma was obtained from 61 metastatic PDAC patients. We found that prognosis was more accurately predicted by RAS mutation detection in plasma than in tissue, and RAS mutation status in plasma was a strong independent prognostic factor for both overall survival (OS) and progression-free survival (PFS). Moreover, RAS MAF in cfDNA was also an independent risk factor for poor OS and was strongly associated with primary tumours in the body/tail of the pancreas and liver metastases. Higher cfDNA levels and fragmentation were also associated with poorer OS and shorter PFS, body/tail tumours, and hepatic metastases, whereas cfDNA fragmentation positively correlated with RAS MAF. Remarkably, the combination of CA19-9 with cfDNAbased biomarkers improved the prognostic stratification of PDAC patients. Furthermore, dynamics of RAS MAF better correlated with patients’ outcome than standard CA19-9 marker. Of note, PDAC is characterized by a highly inflammatory microenvironment, and we found that neutrophil-lymphocyte ratio (NLR) was significantly associated with both OS and PFS. Remarkably, NLR was an independent risk factor for poor OS. Moreover, NLR and platelet-lymphocyte ratio (PLR) positively correlated, and combination of both inflammatory markers significantly improved the prognostic stratification of metastatic PDAC patients. Notably, NLR showed a positive correlation with cfDNA levels and RAS MAF and we found that neutrophil activation contributed to cfDNA content in the plasma of metastatic PDAC patients. Finally, a multiparameter prognosis model was designed by combining inflammatory markers, cfDNA-based markers and CA19-9, which performs as a promising tool to predict the prognosis of metastatic PDAC patients. For the study of cfDNA-based biomarkers in CRC, plasma was obtained from 136 metastatic CRC patients. Likewise, RAS mutation detection in plasma rather than in tissue, more accurately predicted the prognosis of these patients. Moreover, RAS MAF in cfDNA was also associated with poor OS and was strongly related with liver metastases and number of metastatic locations. Higher cfDNA levels and fragmentation positively correlated and they were also associated with worse prognosis and hepatic metastases. Remarkably, the combination of standard CEA marker with plasma RAS status and cfDNA levels improved the prognostic stratification of patients. For the miRNA profiling study, plasma was obtained from 98 metastatic CRC patients enrolled in a clinical phase II trial before receiving FOLFIRI plus aflibercept treatment. A distinct profile of circulating miRNAs was found between responder and non-responder patients. Remarkably, most of these miRNAs were found to have predicted target genes that are involved in angiogenic processes. Accordingly, some of these miRNAs entered in predictive models of response to therapy, progression of disease and survival of patients treated with FOLFIRI plus aflibercept. Among these miRNAs, circulating levels of hsa-miR-33b-5p efficiently discriminated between responders and non-responders patients and predicted the risk of disease progression. In conclusion, our study supports the use of cfDNA-based liquid biopsy biomarkers as clinical tools for the non-invasive prognosis and monitoring of metastatic PDAC patients. Besides, the use of systemic inflammatory markers along with circulating tumour-specific markers greatly improves prognostic power and provides accurate survival risk stratification of these patients. Likewise, the use of both cfDNA-based and miRNA-based liquid biopsy markers may greatly help in the non-invasive prognosis of metastatic CRC patients and in the prediction of their response to anti-angiogenic therapy.
Author: Toledano-Fonseca, Marta
Institution: University of Córdoba
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: green
Award: G2006515080
OpenAlex ID: W6995644836
